February 9, 2017
This is a post hoc analysis of the HALT-PKD clinical trials of renin-angiotensin blockade in patients with ADPKD showed that sodium restriction is beneficial in the management of ADPKD.
May 29, 2016
This core curriculum is a comprehensive overview on ADPKD that should prove to be valuable to both trainee and consultant physicians.
January 24, 2015
This elegant double-blind, placebo-controlled trial shows the addition of an ARB in patients with ADPKD already on an ACE inhibitor did not alter the decline in estimated GFR. Based on this evidence, there seems to be no role for dual RAAS blockade in this population.
November 16, 2014
In patients with early PKD, dual blockage of the RAS system provided no advantage over ACE inhibitor alone. Patients targeted to the standard blood pressure target (120/70 to 130/80 mm Hg) vs a low blood-pressure target (95/60 to 110/75 mm Hg) had reduced annual % increase in total kidney volume (6.6% vs. 5.6%, P=0.006) and more reduction in […]
November 4, 2012
This long awaited clinical trial was presented on November 3, 2012 at the American Society of Nephrology Kidney Week. This multicenter, double-blind, placebo-controlled trial enrolled patients with autosomal dominant polycystic kidney disease who were age 18 to 50 years, had total kidney volume of ≥ 750 ml and an estimated CrCl of ≥ 60 ml per min. […]
Comments Off on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Posted in Polycystic Kidney Disease
June 6, 2010
In this small RCT of 12 months duration, octreotide slowed the progressive increase in liver and kidney volume in patients with polycystic kidney disease and polycystic liver disease. While the findings are encouraging and consistent with other studies, longer and larger clinical trials will be necessary to establish the long-term safety and efficacy of somatostatin […]